Observational studyPloS one2022

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.

Martin Wasserbauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.